David Scadden

Sits on 2 boards. Last updated September 28, 2026

Time on boards

Boards served
2
Current seats
2
Board service
7 years
Director since
2023

7 years of board service in total across 2 boards, counting each seat separately. Longest: Editas Medicine Inc., 3 years.

3 years · Since 2023
3 years · Since 2023

Shareholder support

Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Date Company Transaction Shares Price Value
Jun 18, 2026 Agios Pharmaceuticals Inc. Option exercise +2,816 — —
Nov 12, 2025 Agios Pharmaceuticals Inc. Option exercise +200 $18.09 $3,618
Nov 12, 2025 Agios Pharmaceuticals Inc. Open-market sale −200 $43.84 $8,768
Oct 8, 2025 Agios Pharmaceuticals Inc. Option exercise +200 $18.09 $3,618
Oct 8, 2025 Agios Pharmaceuticals Inc. Open-market sale −200 $41.00 $8,200
Sep 30, 2025 Agios Pharmaceuticals Inc. Option exercise +200 $18.09 $3,618
Sep 30, 2025 Agios Pharmaceuticals Inc. Open-market sale −200 $40.00 $8,000
Aug 27, 2025 Agios Pharmaceuticals Inc. Option exercise +200 $18.09 $3,618
Aug 27, 2025 Agios Pharmaceuticals Inc. Open-market sale −200 $40.00 $8,000
Jul 10, 2025 Agios Pharmaceuticals Inc. Option exercise +1,400 $18.09 $25,326
Jul 10, 2025 Agios Pharmaceuticals Inc. Open-market sale −1,400 $40.00 $56,000
Jun 20, 2025 Agios Pharmaceuticals Inc. Option exercise +2,120 — —
Dec 11, 2024 Agios Pharmaceuticals Inc. Option exercise +200 $18.09 $3,618
Dec 11, 2024 Agios Pharmaceuticals Inc. Open-market sale −200 $46.28 $9,256
Jun 13, 2024 Agios Pharmaceuticals Inc. Option exercise +3,388 — —

Questions about David Scadden

What boards is David Scadden on?

David Scadden sits on the boards of Agios Pharmaceuticals Inc. and Editas Medicine Inc.

How long has David Scadden served on boards?

Our records show at least 7 years of board service across 2 boards, the earliest from 2023.

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.